Plasma Exchange Therapy to Reduce Mortality in Japanese Patients With Diffuse Alveolar Hemorrhage and Microscopic Polyangiitis.
Diffuse alveolar hemorrhage
Five-Factor Score
Microscopic polyangiitis
Mortality
Plasma exchange
Journal
Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy
ISSN: 1744-9987
Titre abrégé: Ther Apher Dial
Pays: Australia
ID NLM: 101181252
Informations de publication
Date de publication:
Apr 2020
Apr 2020
Historique:
received:
06
02
2019
revised:
19
05
2019
accepted:
20
06
2019
pubmed:
25
6
2019
medline:
15
12
2020
entrez:
25
6
2019
Statut:
ppublish
Résumé
Diffuse alveolar hemorrhage (DAH) is well known as a serious complication of microscopic polyangiitis (MPA). We examined the effectiveness of plasma exchange (PLEX) therapy to reduce mortality in Japanese DAH patients with MPA. This retrospective, double-center, observational cohort study included 20 DAH patients with MPA who were admitted to Juntendo University Hospital or Juntendo Koto Geriatric Medical Center between April 1998 and March 2018. The primary outcome was non-disease-specific mortality. The 1-year survival rate of patients with PLEX therapy (N = 4) was higher than that of patients with conventional therapy (N = 16, 75% and 13%, respectively, P = 0.037). Higher values of the 1996 Five-Factor Score (FFS) and 2009 FFS were associated with increased mortality, with hazard ratios of 2.29 (P = 0.040) and 2.41 (P = 0.043), respectively, by Cox univariate analysis. We investigated PLEX therapy for reducing mortality in DAH patients with MPA, and the 1996 FFS and 2009 FFS were both independent prognostic factors.
Identifiants
pubmed: 31233282
doi: 10.1111/1744-9987.12939
doi:
Types de publication
Comparative Study
Journal Article
Multicenter Study
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
208-214Informations de copyright
© 2019 International Society for Apheresis, Japanese Society for Apheresis, and Japanese Society for Dialysis Therapy.
Références
Hogan SL, Nachman PH, Wilkman AS, Jennette JC, Falk RJ. Prognostic markers in patients with antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis. J Am Soc Nephrol 1996;7:23-32.
Lauque D, Cadranel J, Lazor R et al. Microscopic polyangiitis with alveolar hemorrhage: a study of 29 cases and review of the literature. Groupe d'Etudes et de Recherche sur les Maladies “Orphelines” Pulmonaires (GERM“O”P). Medicine (Baltimore) 2000;79:222-33.
Casian A, Jayne D. Management of alveolar hemorrhage in lung vasculitides. Semin Respir Crit Care Med 2011;32:335-45.
Watts RA, Jolliffe VA, Carruthers DM, Lockwood M, Scott DG. Effect of classification on the incidence of polyarteritis nodosa and microscopic polyangiitis. Arthritis Rheum 1996;39:1208-12.
Jennette JC, Falk RJ, Bacon PA et al. 2012 revised international Chapel Hill consensus conference nomenclature of vasculitides. Arthritis Rheum 2013;65:1-11.
Ozaki S, Atsumi T, Hayashi T et al. Severity-based treatment for Japanese patients with MPO-ANCA-associated vasculitis: the JMAAV study. Mod Rheumatol 2012;22:394-404.
Harigai M, Nagasaka K, Amano K et al. Clinical practice guidelines of the Japan Research Committee of the Ministry of Health, Labour, and Welfare for intractable vasculitis for the management of ANCA-associated vasculitis. Mod Rheumatol 2017;2018:1-11.
Ntatsaki E, Carruthers D, Chakravarty K et al. BSR and BHPR guideline for the management of adults with ANCA-associated vasculitis. Rheumatology 2014;53:2306-9.
Schwartz J, Winters JL, Padmanabhan A et al. Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Writing Committee of the American Society for Apheresis: the sixth special issue. J Clin Apher 2013;28:145-284.
Alba MA, Flores-Suarez LF. Seven clinical conundrums in the treatment of ANCA-associated vasculitis. Clin Exp Rheumatol 2013;31(1 Suppl 75):S74-83.
Walsh M, Merkel PA, Peh CA et al. Plasma exchange and glucocorticoid dosing in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis (PEXIVAS): protocol for a randomized controlled trial. Trials 2013;14:73.
Watts R, Lane S, Hanslik T et al. Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. Ann Rheum Dis 2007;66:222-7.
Luqmani RA, Bacon PA, Moots RJ et al. Birmingham vasculitis activity score (BVAS) in systemic necrotizing vasculitis. QJM 1994;87:671-8.
Mukhtyar C, Lee R, Brown D et al. Modification and validation of the Birmingham vasculitis activity score (version 3). Ann Rheum Dis 2009;68:1827-32.
Guillevin L, Lhote F, Gayraud M et al. Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome. A prospective study in 342 patients. Medicine (Baltimore) 1996;75:17-28.
Guillevin L, Pagnoux C, Seror R et al. The five-factor score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French vasculitis study group (FVSG) cohort. Medicine (Baltimore) 2011;90:19-27.
Gallagher H, Kwan JT, Jayne DR. Pulmonary renal syndrome: a 4-year, single-center experience. Am J Kidney Dis 2002;39:42-7.
Hruskova Z, Casian AL, Konopasek P et al. Long-term outcome of severe alveolar haemorrhage in ANCA-associated vasculitis: a retrospective cohort study. Scand J Rheumatol 2013;42:211-4.
Hirayama K, Kobayashi M, Usui J et al. Pulmonary involvements of anti-neutrophil cytoplasmic autoantibody-associated renal vasculitis in Japan. Nephrol Dial Transplant 2015;30(Suppl 1):i83-93.
Falk RJ, Nachman PH, Hogan SL, Jennette JC. ANCA glomerulonephritis and vasculitis: a Chapel Hill perspective. Semin Nephrol 2000;20:233-43.
Klemmer PJ, Chalermskulrat W, Reif MS, Hogan SL, Henke DC, Falk RJ. Plasmapheresis therapy for diffuse alveolar hemorrhage in patients with small-vessel vasculitis. Am J Kidney Dis 2003;42:1149-53.
Jayne DR, Gaskin G, Rasmussen N et al. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol 2007;18:2180-8.
Levy JB, Hammad T, Coulthart A, Dougan T, Pusey CD. Clinical features and outcome of patients with both ANCA and anti-GBM antibodies. Kidney Int 2004;66:1535-40.
West S, Arulkumaran N, Ind PW, Pusey CD. Diffuse alveolar haemorrhage in ANCA-associated vasculitis. Intern Med 2013;52:5-13.
Moussi-Frances J, Sallee M, Jourde-Chiche N. Apheresis to treat systemic vasculitis. Joint Bone Spine 2018;85:177-83.
de Luna G, Chauveau D, Aniort J et al. Plasma exchanges for the treatment of severe systemic necrotizing vasculitides in clinical daily practice: data from the French vasculitis study group. J Autoimmun 2015;65:49-55.
Geri G, Terrier B, Heshmati F et al. Effect of plasma exchange in acute respiratory failure due to anti-neutrophil cytoplasmic antibody-associated vasculitis. Crit Care 2018;22:328.
Nishimura K, Waki D, Kadoba K, Mukoyama H, Yokota T, Murabe H. Efficacy of plasma exchange in anti-neutrophil cytoplasmic antibody-associated vasculitis. Ther Apher Dial 2019;23:248-52.
Jennette JC, Falk RJ. Clinical and pathological classification of ANCA-associated vasculitis: what are the controversies? Clin Exp Immunol 1995;101(Suppl 1):18-22.
Bansal PJ, Tobin MC. Neonatal microscopic polyangiitis secondary to transfer of maternal myeloperoxidase-antineutrophil cytoplasmic antibody resulting in neonatal pulmonary hemorrhage and renal involvement. Ann Allergy Asthma Immunol 2004;93:398-401.
Xiao H, Heeringa P, Hu P et al. Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J Clin Invest 2002;110:955-63.
Abe Y, Tamura N, Yang KS et al. Predictive factors for mortality in elderly Japanese patients with severe microscopic polyangiitis: a retrospective single-center study. Mod Rheumatol 2017;27:315-9.
Sugiyama K, Sada KE, Kurosawa M, Wada J, Makino H. Current status of the treatment of microscopic polyangiitis and granulomatosis with polyangiitis in Japan. Clin Exp Nephrol 2013;17:51-8.
Higgins RM, Goldsmith DJ, Connolly J et al. Vasculitis and rapidly progressive glomerulonephritis in the elderly. Postgrad Med J 1996;72:41-4.
Tarzi RM, Pusey CD. Vasculitis: risks and rewards of treating elderly patients with vasculitis. Nat Rev Nephrol 2011;7:253-5.
Hoganson DD, From AM, Michet CJ. ANCA vasculitis in the elderly. J Clin Rheumatol 2008;14:78-81.
Harigai M, Nagasaka K, Amano K et al. 2017 Clinical practice guidelines of the Japan Research Committee of the Ministry of Health, Labour, and Welfare for intractable vasculitis for the management of ANCA-associated vasculitis. Mod Rheumatol 2019;29:20-30.
Yates M, Watts RA, Bajema IM et al. EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis 2016;75:1583-94.